The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Observational Trial of Real-World Treatment Utilization and Effectiveness of PI3K-inhibitors in CLL/SLL and FL
Official Title: PI3K-Inhibitor Registry Study: Real-World Treatment Utilization and Effectiveness of PI3K-inhibitors in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma and Follicular Lymphoma
Study ID: NCT04342117
Brief Summary: This study will assess whether there are differences in effectiveness and safety outcomes among PI3K-treated patients in a real world registry, compared to patients treated in clinical trials.
Detailed Description: Phase IV, multicenter, prospective observational study in a real world (RW) setting, designed to observe the utilization and effectiveness of PI3K-inhibitor treatment, and HRQoL of patients with CLL/SLL/FL outside the context of a clinical trial.
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
CARTI Cancer Center, Little Rock, Arkansas, United States
Joliet Oncology-Hematology Associates, LTD, Joliet, Illinois, United States
Goshen General Hospital, Goshen, Indiana, United States
McFarland Clinic,PC, Ames, Iowa, United States
St. Agnes Hospital, Baltimore, Maryland, United States
Regional Cancer Care Associates LLC, Bethesda, Maryland, United States
Hattiesburg Clinic, PA, Hattiesburg, Mississippi, United States
Capital Region Medical Center, Jefferson City, Missouri, United States
Oncology Hematology Associates, Springfield, Missouri, United States
NY Cancer and Blood Specialists, Port Jefferson Station, New York, United States
University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States